Indian Scientists Develop Novel Nanoformulation For Parkinson's Treatment
Date
2/3/2025 11:07:21 PM
(MENAFN- Daily News Egypt) Researchers in India have developed a new nanoformulation that may improve the safety and efficacy of Parkinson's disease treatment, IANS, a partner of TV BRICS , reported.
The scientists created a targeted drug delivery system for the sustained release of 17β-oestradiol (E2), a hormone crucial for managing Parkinson's symptoms. Parkinson's disease, a progressive neurodegenerative disorder, is linked to an imbalance of E2 in the brain. However, wider therapeutic use of the hormone has been hampered by potential side effects and a limited understanding of its molecular mechanisms.
To overcome these challenges, the researchers used dopamine receptor D3 (DRD3)-conjugated chitosan nanoparticles to deliver E2 directly to the brain, thereby enhancing its therapeutic potential. This innovative approach protects against mitochondrial damage by inhibiting calpain translocation.
The study also revealed a critical role for BMI1, a regulator of mitochondrial homeostasis, in Parkinson's disease. The nanoformulation successfully restored BMI1 expression by preventing its degradation via calpain inhibition, potentially offering a new target for neuroprotective therapies.
MENAFN03022025000153011029ID1109163739
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.